Vitiligo
☆ Ann an toraidhean 2022 Stiftung Warentest às a’ Ghearmailt, cha robh sàsachd luchd-cleachdaidh le ModelDerm ach beagan nas ìsle na le co-chomhairlean telemedicine pàighte.
Tha vitiligo de na corragan nas duilghe a làimhseachadh na raointean eile. A bharrachd air a bhith mì-mhodhail gu cosmaigeach, tha vitiligo àbhaisteach agus chan eil e gabhaltach. Ann an dermatology, is e an làimhseachadh as èifeachdaiche phototherapy no làimhseachadh laser (excimer) 2-3 tursan san t-seachdain airson co-dhiù 1 bliadhna. Mura h-urrainn dhut a dhol don ospadal gu tric airson adhbharan ionmhais no leis gu bheil thu trang, faodaidh tu feuchainn air inneal phototherapy a tha ceadaichte airson a chleachdadh san dachaigh.
Sùilean sùla
Vitiligo air làimh
References
Tha vitiligo na eas-òrdugh craiceann cumanta a dh’ adhbhraicheas pìosan de chraiceann geal air sgàth call melanocytes. Tha rannsachadh o chionn ghoirid a’ sealltainn gur e galar fèin-dìon a th’ ann. Ged a thathas gu tric ga fhaicinn mar chùis cosmaigeach, faodaidh e buaidh mhòr a thoirt air sunnd inntinn agus beatha làitheil. Ann an 2011, chuir eòlaichean seòrsa ris an canar segmental vitiligo fa leth bho chàch.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Tha grunn roghainnean leigheis aig euslaintich gnìomhach vitiligo, leithid glucocorticoids siostamach, phototherapy, agus immunosuppressants siostamach. Is dòcha gum faigh euslaintich vitiligo seasmhach faochadh bho corticosteroids gnàthach, luchd-dìon calcineurin aig an àm, phototherapy, agus modhan tar-chuir. Tha adhartasan o chionn ghoirid ann a bhith a’ tuigsinn pròiseasan bunaiteach vitiligo air leantainn gu leasachadh leigheasan cuimsichte. An-dràsta, is e luchd-dìon JAK an fheadhainn as gealltanach, a’ tabhann deagh fhulangas agus builean gnìomh, a dh’ aindeoin an cunnart gun tèid galairean falaichte agus fo-bhuaidhean siostamach a tha cumanta le riochdairean dìon dìon eile a chuir an gnìomh. Tha rannsachadh leantainneach ag amas air prìomh cytokines a tha an sàs ann an leasachadh vitiligo (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF) a chomharrachadh. Tha casg air na cytokines sin air gealladh a nochdadh ann am modalan bheathaichean agus cuid de dh’ euslaintich. A bharrachd air an sin, tha sgrùdaidhean air miRNA-based therapeutics agus adoptive Treg cell therapy a’ dol air adhart.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Chan eil fios air leigheas sam bith airson vitiligo. Dhaibhsan le craiceann aotrom, is e grian-grèine agus makeup a h-uile rud a thathas a’ moladh mar as trice. Faodaidh roghainnean làimhseachaidh eile a bhith a’ toirt a-steach uachdaran steroid no phototherapy.
○ làimhseachadh
#Phototherapy
#Excimer laser
#Tacrolimus ointment